Adapted ECHO-7 virus Rigvir® immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study
The results of a retrospective study using the oncolytic virus Rigvir® effectiveness published online by Melanoma Research, July 15, 2015 http://journals.lww.com/melanomaresearch/Fulltext/2015/10000/Adapted_ECHO_7_virus_Rigvir_immunotherapy.7.aspx
The study reveals that the stage IB-IIC melanoma patients treated with Rigvir® were 4 to 6 times more likely to survive than those who, following the current guidelines for the treatment of melanoma, received no therapy and were observed only. Moreover, Rigvir® demonstrated an outstanding safety profile because there was no record of any untoward side effect from Rigvir® treatment or its discontinuation. The results indicate that a significant number of melanoma patients would benefit from prolonging the survival with Rigvir® treatment.
Source: Melanoma Research. 2015 Jul 24. Doniņa S, Strēle I, Proboka G, Auziņš J, Alberts P, Jonsson B, Venskus D, Muceniece A.
Progression-free period in II stage melanoma patients
The results of a retrospective study published by Latvijas Ārsts indicated outstanding progression-free period in stage II melanoma patients treated with RIGVIR® Oncolytic virotherapy.
Source: Latvijas Ārsts. 2012, Nr.5. Doniņa et al.